Oxford’s COVID-19 vaccine will be more effective on patients when given as two full doses rather than one full dose and one half booster dose. Oxford University reported on Thursday.
The university has published interim late stage trial results regarding the Oxford vaccine registered by AstraZeneca for license. It states that the vaccine is more effective on patients when given two full doses. However, more work needs to be done on these results.
Detailed information on the first and second phase tests was published on Thursday. But no information was given about the entire dose after half the dose, which Oxford said was unplanned. However, it was approved by the regulators.
In fact, in November, the UK pharma company AstraZeneca and Oxford University admitted an error in the trial of their shared vaccine. Those who were given low doses of the vaccine during the vaccine test had an impact of 90 percent, while those who were given two full doses were found to have only 62 percent.
As reported earlier, according to the results of the final phase of the Oxford Vaccine trial, only three out of about 24,000 people saw the side effects of the vaccine. According to the results published in the medical journal Lancet, neither of those who were given the vaccine died, nor was anyone admitted to the hospital.
Research published in the Lancet showed that during the test, the corona vaccine yielded 62 percent effective capacity when given two full doses, and about 90 percent effective at first half dose and then full dose. Now the pharmaceutical company AstraZeneca has expressed hope that the Corona vaccine will be approved by the regulatory body in the coming week.